P-33 Prognostic impact of single organ pulmonary metastasis in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy

Abstract

The impact of single-organ metastases to lung on progression free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) has not been studied. Recognizing the differences in prognosis and chemotherapeutic efficacy by metastatic organs can help optimize treatment strategy. Consecutive mCRC patients who were treated with second-line FOLFIRI and vascular endothelial growth factor (VEGF) inhibitorswere retrospectively enrolled. Overall response rate (ORR), PFS, OS were assessed according the presence of single organ pulmonary metastasis. A total of 289 patients were treated with FOLFIRI +VEGF inhibitors.26 patients (9.0%) have a single organ pulmonary metastasis. Characteristic of patients with single organ pulmonary metastasis were tended to be high frequency of left sided primary site (P = 0.076) and significantly low level of tumor markers at initiation of chemotherapy (CEA: P = 0.0044, CA19-9: P = 0.00008). Patients with single organ pulmonary metastasis had significantly longer PFS and OS than those without (Median PFS: 29.6 months vs 6.1 months P = 0.00025, Median OS: 35.3 months vs 18.7 months P = 0.0001). In multivariate analysis, single organ pulmonary metastasis was independent predictor of longer PFS and OS (PFS: HR 0.36, P = 0.0009, OS: HR 0.28, P = 0.0004). Single organ pulmonary metastasis has better impact on PFS and OS in mCRC patients treated with FOLFIRI and VEGF inhibitors as second-line chemotherapy.